Sichuan Biokin Pharma Files for $500 Million Hong Kong IPO
- Goldman, JPMorgan and Citic are joint sponsors for share sale
- Biokin shares soared in Shanghai after listing in city in 2023
This article is for subscribers only.
Sichuan Biokin Pharmaceutical Co. filed for a Hong Kong listing that could raise about $500 million, according to people familiar with the matter, making it one of the larger deals in the city’s pipeline.
The drugmaker, which is already listed in Shanghai, filed a preliminary prospectus dated Wednesday, without going into detail on the size of the initial public offering. Goldman Sachs Group Inc., JPMorgan Chase & Co. and Citic Securities Co. are joint sponsors for the share sale, the prospectus showed.